

New Technologies and Diagnostic Tools

Plasma glycoalbumin as a source of GPIIb/IIIa in the von Willebrand factor ristocetin cofactor ELISA

Karen Vanhoorelbeke, Inge Pareyn, Agota Schlamadinger¹, Stephan Vauterin, Marc F. Hoylaerts², Jef Arnout², Hans Deckmyn

Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium ¹2nd Department of Medicine, University of Debrecen, Debrecen, Hungary

²Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium

Summary

We have previously demonstrated that the von Willebrand factor ristocetin cofactor activity (VWF:RCo), used in the diagnosis of von Willebrand disease (VWD), can be accurately determined via ELISA by measuring the ristocetin-induced binding of VWF to a captured recombinant fragment of GPIIb/IIIa (rfGPIIb/IIIa, AA 1–289) (Vanhoorelbeke et al., *Thromb Haemost* 2000; 83: 107–13). This ELISA is more reliable than the currently used platelet agglutination test. Normal plasma contains relatively high concentrations of glycoalbumin, a proteolytic fragment of GPIIb/IIIa. We therefore studied whether non-purified plasma glycoalbumin can replace rfGPIIb/IIIa in our ELISA. Of 42 anti-GPIIb/IIIa monoclonal antibodies (MAbs) capable of binding plasma glycoalbumin, only one MAb captured glycoalbumin in a spatial orientation exposing the VWF-binding site in glycoalbumin, allowing a specific and dose-

dependent ristocetin-mediated VWF-binding. Intra- and inter-assay variability were comparable with those for the rfGPIIb/IIIa based VWF:RCo ELISA. The VWF:RCo activity of plasma from 33 normal individuals, 19 type 1, 16 type 2A, 9 type 2B, 8 type 2M and 7 type 3 VWD patients was determined with this ELISA and allowed a clear identification of VWD patients. Furthermore, determination of the VWF:RCo/VWF:Ag ratio resulted in the discrimination between type 1 and type 2 VWD patients. Results for the glycoalbumin based and the rfGPIIb/IIIa based VWF:RCo ELISAs were in good agreement ($r = 0.943$). There was also a good correlation between the glycoalbumin based ELISA and the standard platelet agglutination test ($r = 0.963$). In conclusion, to diagnose VWD, a VWF:RCo ELISA based on antibody immobilized plasma glycoalbumin can be performed reliably.

Keywords

Plasma glycoalbumin, von Willebrand disease (VWD), von Willebrand ristocetin cofactor activity (VWF:RCo) assay

Thromb Haemost 2005; 93: 165–71

Introduction

Von Willebrand disease (VWD) is one of the most frequent inherited bleeding disorders characterized by typical mucocutaneous bleeding symptoms (epistaxis, menorrhagia). VWD is due to quantitative (type 1 and type 3) and/or qualitative (type 2A, 2B, 2M and 2N) deficiencies (1) in the plasma glycoprotein von Willebrand factor (VWF), a protein known to play a role in primary haemostasis (2, 3). VWF is a multimeric protein with a M_r of up to 20 million and is synthesized by endothelial cells and megakaryocytes. By forming a bridge between the platelets through glycoprotein (GP)Ib/V/IX and the exposed collagen in the damaged vessel wall, VWF is responsible for the initiation of platelet plug formation especially in regions of high shear stress.

VWF also binds coagulation factor VIII (FVIII) thus protecting it from degradation.

Different laboratory tests aim at correctly diagnosing VWD, such as the bleeding time (BT), the VWF antigen level (VWF:Ag) determination, the VWF ristocetin cofactor activity (VWF:RCo) measurement and the VWF collagen-binding activity (VWF:CBA) measurement. For the identification of the different subtypes of VWD additional tests such as multimer analysis, ristocetin-induced platelet agglutination and FVIII-binding assays are needed (3).

The VWF ristocetin cofactor assay (VWF:RCo) measures the activity of VWF in plasma. In the presence of ristocetin (4, 5), high VWF multimers then acquire a higher affinity for platelet GPIIb/V/IX (6). The standard VWF:RCo techniques measure the

Correspondence to:
Karen Vanhoorelbeke
Laboratory for Thrombosis Research
IRC, KU Leuven Campus Kortrijk
E. Sabbelaan 53, 8500 Kortrijk
Belgium
Tel.: + 32 56 246422, Fax: + 32 56 246997
E-mail: Karen.Vanhoorelbeke@kula.ac.be

Received June 29, 2004
Accepted after revision October 18, 2004

Financial support:
KV is supported by a postdoctoral fellowship of the 'Fonds voor Wetenschappelijk Onderzoek Vlaanderen' Belgium. This work was supported by GOA/02/09.

Republished online December 8, 2004 DOI: 10.1160/TH04-04-0402

agglutination of fixed donor platelets with patient plasma in the presence of ristocetin (7, 8). However, this assay suffers from high inter-assay and intra-assay variability due to the use of donor platelets and the sometimes difficult interpretation of the platelet agglutination profile (9). To improve the diagnosis of VWD, we have recently proposed a new and more reproducible ELISA to determine the VWF:RCo activity (10, 11). In this assay, a recombinant fragment of GPIIb α (rfGPIIb α AA 1–289), that contains the VWF binding site of the receptor, is captured on an anti-GPIIb α monoclonal antibody (MAb). Different dilutions of patient plasma are added in the presence of a fixed concentration of ristocetin and bound VWF is detected using polyclonal anti-VWF antibodies labelled with horse radish peroxidase (HRP). The VWF:RCo in the patient plasma is calculated by comparison to VWF-binding in a normal plasma pool.

We have now extended the applicability of this ELISA by demonstrating that plasma glycofocalicin can be used instead of rfGPIIb α to mediate the ristocetin-induced recruitment of VWF to GPIIb α . Glycofocalicin is a hydrophilic proteolytic fragment of GPIIb α with a M_r of ~ 135 000 known to be highly glycosylated (56.5% (w/w) carbohydrate) (12). The platelet derived calcium dependent protease calpain was believed to be responsible for the proteolysis of GPIIb α (13, 14), but recently a role for matrix metalloproteases (MMP) has been demonstrated (15, 16). Glycofocalicin is found in normal plasma at a concentration of 1–3 $\mu\text{g/ml}$ (17, 18) and plasma levels may reflect the turnover of platelets and would therefore be an aid in the classification of thrombocytopenic disorders (19, 20). Glycofocalicin used in the present study was not purified from plasma but captured on an anti-GPIIb α MAb. The choice of such antibody however was critical as we found only one single MAb capable of presenting glycofocalicin in an optimal conformation necessary to allow ristocetin-induced VWF-binding.

Materials and methods

Materials

The plasma pool of 25 normal plasmas as a source of VWF was prepared as described and was therefore considered to contain 10 $\mu\text{g/ml}$ VWF and 1 U/ml VWF:RCo (10). Citrated Platelet Poor Plasma (PPP) used as a source of glycofocalicin was obtained from single normal individuals and was prepared as described (10). Plasmas from VWD patients were either from the 2nd Department of Medicine, University of Debrecen, Hungary or were a kind gift of Dr. K. Peerlinck (Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium). Plasmas were always incubated for 5 min at 37°C before use. Purified VWF was from the Red Cross Belgium. The rfGPIIb α was obtained from CHO cells expressing soluble rfGPIIb α and was purified and characterized as described (10). Ristocetin was from American BioProducts (abp) (New Jersey, USA).

Monoclonal antibodies (MAb) and platelet glycofocalicin

Monoclonal anti-GPIIb α antibodies were prepared in house by immunizing Balb/C mice with purified GPIIb α (21). Anti-GPIIb α MAb 2D4 captures rfGPIIb α in an active conformation (10), MAb 6B4 inhibits the ristocetin-induced VWF-binding to rfGPIIb α (AA1–298) (22) and MAb 11A11 is a neutral anti-GPIIb α

antibody. MAbs were biotinylated using NHS LC biotin (sulfo-succinimidyl 6-[biotinamido] hexanoate) Pierce (Rockford, IL) according to the manufacturer's instructions.

Platelet glycofocalicin was isolated from 20 units outdated platelets (Red Cross, Roeselare, Belgium) as described using 3M KCl (23) and purified on a Wheat germ Lectin Sepharose[®] 6MB column (Amersham Biosciences, Uppsala, Sweden) followed by loading on a Resource Q column (Amersham Biosciences).

VWF:RCo ELISA using plasma glycofocalicin

Microtiter plates (96 well, Greiner, Frickenhausen, Germany) were coated overnight with anti-GPIIb α MAbs (5 $\mu\text{g/ml}$ in phosphate buffered saline (PBS)) at 4°C. Wells were blocked with 3% milk powder in PBS for 2 hours at room temperature (RT). Anti-GPIIb α MAbs were saturated with a constant amount of glycofocalicin using a 1/2 dilution of PPP (in TBST) for 1.5 hour at 37°C. A 1/2 dilution series of plasma pool (as a VWF source and consisting of a pool of 25 normal plasmas, cfr. above) starting from a 1/32 dilution (in TBST) was added in the presence of a constant amount of ristocetin for 1.5 hour at 37°C. Bound VWF was detected using rabbit anti-human VWF antibodies labelled with HRP (anti-VWF-Ig-HRP) (Dako) for 1 hour at RT. Visualisation was performed with orthophenylenediamine (OPD, Sigma, St. Louis, USA) and H₂O₂. The colouring reaction was stopped with 4M H₂SO₄. After each incubation step, plates were washed 3 times with TBST after coating and blocking steps and 9 times elsewhere.

To determine the VWF:RCo activity in normal plasmas or plasmas of VWD patients, a standard curve was constructed from the mean data of 4 assays where each time 6 dilutions (1/32, 1/64, 1/128, 1/256, 1/512, 1/1024) of the normal plasma pool were tested. In the normal plasma pool, the VWF:RCo was set as 1 U/ml. The linear part of the curve was fitted using linear regression and the equation was used to calculate the VWF:RCo in normal or patient plasmas. To obtain these values, 4 dilutions (1/32, 1/64, 1/128 and 1/256) of normal or patient plasma were tested in duplicate in the same ELISA assay as the plasma pool and the VWF:RCo values of the 1/128 and 1/256 dilutions (dilutions situated in the linear part of the standard curve) were calculated using the standard curve. The mean of these 4 data resulted in the VWF:RCo in these plasmas. Four dilutions of patient plasma are performed in order to have a good estimate of the quality of the binding curve.

The VWF:RCo ELISA using rfGPIIb α was performed and calculated as described except that 2D4 coated wells were saturated with 1 $\mu\text{g/ml}$ of rfGPIIb α (10).

VWF:RCo in plasma spiked with purified VWF

The ELISA was performed as described in the VWF:RCo ELISA using plasma glycofocalicin except that to the 1/32 dilution of plasma pool (final volume of 500 μl) either no purified VWF or 6.6, 13.2 or 19.8 mU purified VWF was added in the presence of a constant amount of glycofocalicin. Next, 200 μl of the above solution was applied to the first well and then 1/2 dilutions were performed. The ristocetin-induced VWF-binding was further performed as described above.

The VWF:RCo of purified VWF was determined using the normal plasma pool as a reference.

Competition ELISAs

To study the competition between VWF and anti-GPIIb MAbs for the binding to plasma glycofocalicin, the ELISA was performed as described for the VWF:RCo ELISA except that a dilution series of the inhibitory anti-GPIIb MAbs was added to the wells containing the captured glycofocalicin for 30 min at RT. Next, a solution containing plasma pool (final dilution 1/32) and ristocetin (final concentration 1 mg/ml) were added for another hour at 37°C. Bound VWF was detected with anti-VWF-Ig-HRP.

Affinity chromatography

Plasma was depleted of glycofocalicin using affinity chromatography. The anti-GPIIb MAb 24B3 was coupled to CNBr-activated Sepharose® 4B (Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's instructions. The column was equilibrated with TBS, 0.4 mM CHAPS (Boehringer Mannheim, Mannheim, Germany) and normal plasma pool containing 1 mM N-ethylmaleimide (ICN, Ohio, USA), 1 mM leupeptin (Sigma) and 1 mM PMSF (Sigma) was applied on the column. Plasma depleted of glycofocalicin was collected in the flow through. The column was regenerated using 3 cycles of washing with 0.1 M glycine, pH 2.8 followed by TBS. The presence of residual glycofocalicin in the flow through was determined by ELISA as described for the capturing of glycofocalicin on anti-GPIIb MAbs. To check whether VWF levels remained unchanged after affinity chromatography a VWF:Ag ELISA was performed as described (10).

Results

VWF:RCo ELISA using plasma glycofocalicin instead of rfGPIIb α as a GPIIb α source

To investigate whether glycofocalicin present in plasma could be an alternative source for rfGPIIb α in the VWF:RCo ELISA, we have attempted to use non-purified plasma glycofocalicin by capturing it from human plasma using anti-GPIIb MAbs. We screened 42 anti-GPIIb MAbs to determine whether any of these could capture plasma glycofocalicin and support the ristocetin-induced VWF-binding. Of the 42 MAbs screened, 27 MAbs were able to capture glycofocalicin directly from plasma, albeit with different affinities (not shown). However, only one, i.e. MAb 24B3, could capture plasma glycofocalicin in such a way that the ristocetin-induced VWF-binding to MAb 24B3-bound glycofocalicin paralleled that found for 2D4-captured rfGPIIb α (Fig. 1); thus reaching A (490 nm) values high enough to make a robust readout possible (A (490 nm) 0.83 ± 0.11 , $n=3$). The same results were obtained using glycofocalicin purified from outdated platelets (not shown). In contrast, when, for example, MAb 2D4, i.e. the antibody used to capture rfGPIIb α in the reported ELISA, was used to capture plasma glycofocalicin, only a low level of ristocetin-induced VWF-binding was observed (Fig. 1), resulting in A (490 nm) values not high enough for a robust readout (a 1/32 dilution of plasma pool resulted in plateau values of A (490 nm) = 0.37 ± 0.11 , Fig. 1).

In conclusion, when presented by MAb 24B3, plasma glycofocalicin appeared to be suited for a VWF:RCo assay and is a more practical alternative for the 2D4 captured rfGPIIb α .




Figure 1: VWF:RCo determination in ELISA with either MAb 24B3-captured plasma glycofocalicin or MAb 2D4-captured rfGPIIb α . Wells were coated with either MAb 2D4 (●, ■) or 24B3 (▲) and were saturated with either a constant amount (1 μ g/ml) of rfGPIIb α (■) or plasma glycofocalicin (1/2 plasma dilution) (●, ▲). VWF-binding to rfGPIIb α and glycofocalicin was studied in the presence of 760 μ g/ml and 1 mg/ml ristocetin respectively. Different dilutions of a plasma pool were added and bound VWF was detected using anti-VWF-Ig-HRP. ($n = 3$, mean \pm s_D, 100 % A (490 nm) values = 0.99 ± 0.16).

Optimization and validation of the VWF:RCo ELISA using plasma glycofocalicin

Binding of VWF to 24B3 captured plasma glycofocalicin in the presence of different ristocetin concentrations revealed that maximal VWF-binding occurs when induced by 1 mg/ml ristocetin (Fig. 2A). This ristocetin concentration was therefore used in all following experiments. Concentrations of 1.2 mg/ml and 1.5 mg/ml of ristocetin were also tested but resulted in too high background values. The VWF-binding was specific as no binding was observed in the absence of ristocetin or in the presence of the inhibitory anti-GPIIb MAb 6B4 (Fig. 2B), but not of a control antibody.

To test whether the choice of plasma as a source of glycofocalicin would influence the extent of the ristocetin-induced binding of VWF in this ELISA and thus the determination of the VWF:RCo, 19 different normal plasmas were selected to saturate 24B3 with glycofocalicin. The ristocetin-induced VWF-binding was then studied using the normal plasma pool (as a source of VWF) in dilutions of 1/32 and 1/64. Figure 3A demonstrates that most normal plasmas can be used as a source of glycofocalicin. The coefficient of variation ($CV=(s_D/\text{mean})\cdot 100$) for the 1/32 and 1/64 dilution was 10.4 % ($n=19$) and 11 % ($n=19$) respectively.

Next, the influence of the presence of glycofocalicin in the plasma used as VWF source in the VWF:RCo ELISA was studied. The binding of VWF present in normal plasma, i.e. containing glycofocalicin, or in plasma depleted of glycofocalicin, to 24B3 captured plasma glycofocalicin was compared. Normal plasma was depleted of glycofocalicin through affinity chromatography using an anti-GPIIb MAb. The absence of glycofocalicin and a normal VWF concentration were both confirmed in ELISA. No major effect of the absence of glycofocalicin was seen when a 1/32 dilution (or higher dilutions) of plasma as a source of VWF was tested (Fig. 3B), confirming that at the final plasma dilution tested, plasma glycofocalicin does not compete with antibody bound glycofocalicin for VWF-binding.




Figure 2: Sensitivity and selectivity of VWF-binding to captured plasma glycolalicin. (A) 24B3 coated wells were saturated with plasma glycolalicin by adding a constant amount of plasma and VWF-binding was performed as described under Figure 1 in the presence of 0 (□), 0.5 (○), 0.76 (△) and 1 mg/ml ristocetin (▽). (n = 3, mean ± s_D, 100 % A (490 nm) values were 1.11 ± 0.3). (B) The VWF:RCo ELISA was performed as described under A but increasing concentrations of the inhibiting anti-GPIIb MAb 6B4 (■) or non-inhibiting anti-GPIIb MAb 11A11 (●) were added to plasma glycolalicin saturated wells for 30 min before constant amounts of plasma pool as a source of VWF (final dilution 1/32) in the presence of 1 mg/ml ristocetin were added for another hour. (n = 3, mean ± s_D).

To then validate plasma glycolalicin for application in the VWF:RCo assay, the intra-assay variability was determined by testing 6 dilutions of plasma pool on 8 replicates in one run. The CV was less than 10% for each dilution point (6%, 5%, 9%, 7%, 5% and 7% respectively). The inter-assay variability was determined by testing the same plasma dilutions on six replicates over 3 days and by 2 different investigators. The maximum CV observed for each data point was 10%, 9%, 9%, 9% and 9.5% respectively. The detection limit (DL) and quantification limit (QL) were determined by assaying 9 dilutions (1/32 to 1/8192) of plasma pools in 3 different ELISAs, and each time the zero standard was obtained from a plasma of a type 3 VWD patient. The DL (defined as 3SD above the mean of zero standard) was 0.0005 U/ml. The QL, the minimum concentration that can be measured from assay to assay with CV < 20% was 0.0005 U/ml.

We also investigated whether VWF:RCo activities of more than 1U/ml could be correctly measured. We therefore spiked 16




Figure 3: Variability of the plasma source of glycolalicin (A) and influence of the presence of glycolalicin in the plasma used as VWF source (B) in the VWF:RCo ELISA. (A) 24B3 coated wells were saturated with glycolalicin from 19 different plasmas (bar 1 to 19) by adding a constant amount of each plasma. Normal human plasma pool (as a source of VWF) was added in a 1/32 and 1/64 dilution in the presence of 1 mg/ml ristocetin. Bound VWF was detected using anti-VWF-Ig-HRP. Only A 490 nm values of 1/32 dilutions are shown. Last bar represents the mean ± s_D of the 19 samples tested. (B) Glycolalicin from plasma was captured by MAb 24B3 and dilution series starting from a 1/32 dilution of the normal plasma pool (●) or of plasma affinity depleted of glycolalicin (■) were added in the presence of 1 mg/ml of ristocetin. Bound VWF was detected with anti-VWF-Ig HRP. (n = 3, mean ± s_D, 100 % A (490 nm) values were 1.04 ± 0.29).

mU (in 500 µl) of a normal plasma pool (1U/ml original activity) with 6.6 mU, 13.2 mU or 19.8 mU of purified VWF. Table 1 shows that the VWF:RCo in plasmas containing up to 228 % VWF:RCo activity when compared to the VWF:RCo present in a normal plasma pool, still can be accurately determined in this ELISA.

VWF:RCo in plasma from normal individuals and VWD patients

The VWF:RCo determined using the VWF:RCo ELISA with captured plasma glycolalicin was determined in plasma of 33 normal individuals and ranged from 0.46 U/ml to 2.7 U/ml (Fig. 4).

The VWF:RCo values ranged from 0.09 to 0.48 U/ml when measured in 19 type 1 VWD plasmas, from 0 to 0.4 U/ml in 16 type 2A patients, from 0 to 0.66 U/ml in 9 type 2B patients and from 0.01 to 0.16 U/ml in 8 type 2M patients. For the 7 type 3 patient plasmas, no VWF:RCo activity was detected (Fig. 4).

Table 1: Determination of VWF:RCo in plasmas containing up to 228% VWF:RCo. To 16 mU of normal plasma pool different mU of purified VWF were added, the final expected VWF:RCo was calculated and was next determined using the VWF:RCo ELISA.

mU VWF:RCo added to plasma pool	Calculated VWF:RCo (U/ml)	Measured VWF:RCo (U/ml)	CV (%) of measured VWF:RCo
6.6	1.45	1.75 ± 0.21	12
13.2	1.85	2.08 ± 0.12	6
19.8	2.28	2.75 ± 0.21	8




Figure 4: VWF:RCo levels from normal individuals and from VWD patients. Data points represent the VWF: RCo in the plasma from 33 normal individuals, 19 type 1 VWD patients, 16 type 2A, 9 type 2B, 8 type 2M and 7 type 3 VWD patients. Each data point represents the mean of the VWF:RCo obtained from 2 analysis of 2 different plasma dilutions ($n = 4$).

Comparison of the current ELISA with other methods

To compare the current ELISA where we use 24B3-captured plasma glycofibrinogen with our previous ELISA where 2D4-captured rFgPIb α is used to measure the ristocetin-induced VWF-binding, VWF:RCo was also determined using the latter test on 22 of the 33 normal plasmas and the values ranged from 0.34 U/ml to 0.99 U/ml. The VWF:RCo of most of the VWD plasmas (17 type 1, 10 type 2A, 1 type 2B and 3 type 3 VWD) have previously been determined in the VWF:RCo ELISA using the rFgPIb α (10). Figure 5 shows that there is a good correlation ($r = 0.943$) between the data obtained using either plasma glycofibrinogen or rFgPIb α as a source of GPIIb/IIIa in the VWF:RCo ELISA.

The data obtained with the glycofibrinogen based VWF:RCo ELISA furthermore correlated with those previously obtained with the classical agglutination method, as a correlation of $r = 0.963$ was calculated (Fig. 6). Platelet agglutination data were determined at the Center for Molecular and Vascular Biology, KU Leuven, Leuven Belgium or at the 2nd Department of Medicine, University of Debrecen, Hungary and were available for 11 normal plasmas, 19 type 1, 16 type 2A, 9 type 2B, 8 type 2M and 7 type 3 plasmas.




Figure 5: Scatter plot analysis of VWF:RCo determined in the VWF:RCo ELISA using plasma glycofibrinogen or rFgPIb α . VWF:RCo values were determined in the VWF:RCo ELISA using either 24B3 captured plasma glycofibrinogen or 2D4 captured rFgPIb α .




Figure 6: Scatter plot analysis of VWF:RCo determined in the VWF:RCo ELISA using plasma glycofibrinogen or in the platelet agglutination test. Values measured in the ELISA test using glycofibrinogen are the same as in Figure 4 and the values determined in the platelet agglutination test were obtained at the Center for Molecular and Vascular Biology, KU Leuven, Leuven Belgium or at the 2nd Department of Medicine, University of Debrecen, Hungary.

Discrimination between type 1 and type 2 VWD patients using the glycofibrinogen based VWF:RCo ELISA

Calculation of the VWF:RCo/VWF:Ag ratio allows a discrimination between normals, type 1 patients on the one hand and type 2 VWD patients on the other hand (24). VWF:RCo/VWF:Ag ratios < 0.7 classify the patients as type 2 VWD. Table 2 demonstrates that for all normal plasmas VWF:RCo/VWF:Ag ratios > 0.7 are obtained. Only one type 2 patient is incorrectly diagnosed using the glycofibrinogen based VWF:RCo ELISA, while for 10 type 2 patients VWF:RCo/VWF:Ag ratios < 0.7 were obtained. For the type 1 patients, 6 are incorrectly diagnosed with both the ELISA and the agglutination test, may be questioning the earlier typing. Of the other type 1 patients, 3 VWF:RCo/VWF:Ag ratios are < 0.7 , when using the ELISA and 1 using the agglutination test.

Table 2: VWF:RCo/VWF:Ag ratios to discriminate between type 1 and type 2 patients. VWF:RCo was determined using either the VWF:RCo ELISA based on 24B3-captured plasma glyocalicin (ELISA) or the platelet agglutination test (agglutination). VWF:RCo/VWF:Ag < 0.7 should identify type 2 patients. Data in bold are not in agreement with this ratio, and thus might result in misdiagnosis of VWD patients.

normals		Type 2A	
ELISA	agglutination	ELISA	agglutination
0.9	1.35	0.11	1.33
0.9	2.0	0.02	0.27
0.9	ND	0.23	0.13
0.94	1.06	0.09	1.12
0.79	1.02	0.04	0.44
1.05	1.09	0.1	1.22
0.93	0.91	0.06	0.75
0.99	0.98	0.04	0.75
0.98	0.99	0.07	0.8
1.07	0.95	0.05	0.57
0.89	0.86	0.22	0.22
1.22	1.18	0.48	0.26
		0.4	0.21
		0.32	0.16
		0.4	0.34
		0.56	0.52
Type 1		Type 2B	
ELISA	agglutination	ELISA	agglutination
0.56	0.63	0.03	0.38
1.14	0.98	0.13	0.28
1.19	1.06	0.43	0.32
0.97	0.51	0.43	0.56
0.59	1.02	0.63	0.85
1.02	1.09	0.49	0.49
0.8	0.76	0.19	0.28
0.72	1.1	0.02	0.12
0.45	0.75	0.5	0.59
0.68	0.53		
0.26	0.59		
		Type 2M	
		ELISA	agglutination
0.32	0.38		
0.48	0.71	0.28	0.96
0.43	1.43	0.22	0.72
0.46	0.42	0.36	0.75
0.26	0.44	0.12	0.39
0.88	1.15	0.75	0.5
0.73	0.7	0.38	0.28
0.92	0.72	0.27	0.27
		0.56	0.56

Discussion

We have recently developed and validated an ELISA to determine the VWF:RCo (10, 11) and demonstrated that this test largely overcomes the drawbacks of the routinely used agglutination test, one of the important tests used in the diagnosis of VWD patients. The advantages of this test were recently confirmed by Federici et al. (25). In this ELISA a rFGPIb α is used, expressed by CHO cells, to measure the ristocetin-induced binding of VWF. However, in order to facilitate the accessibility of this ELISA to the clinical laboratory, an alternative for the rFGPIb α is needed, as the production and purification of rFGPIb α is cumbersome and expensive. We reasoned that glyocalicin could be a good alternative. Two sources of glyocalicin were of interest: either produced by proteolytic digestion of the platelet receptor GPIb/V/XI complex (12, 23) or selected from plasma itself, known to contain glyocalicin levels around 1–3 μ g/ml in normal individuals (17, 18). The latter seemed preferable in view of the possibility to capture glyocalicin directly from the plasma without the need for further purification. Twenty seven of the 42 screened anti-GPIb α MAbs were able to capture glyocalicin from plasma. However, only MAb 24B3 was able to efficiently capture glyocalicin to enable ristocetin-induced VWF-binding. The resulting ristocetin-induced VWF-binding to 24B3-bound plasma glyocalicin was specific, as no binding was observed in the absence of ristocetin and since VWF-binding could be inhibited by function blocking anti-GPIb MAbs.

The VWF:RCo determined in the glyocalicin-based ELISA correlated well with the VWF:RCo determined in the platelet agglutination test ($r = 0.963$) and in the rFGPIb α -based ELISA assay ($r = 0.943$). Determination of ratio of VWF:RCo to VWF:Ag helps distinguishing type 1 and type 2 VWD patients as low ratios (<0.7) identify dysfunctional type 2 VWF. Combination of the VWF:RCo determined in the glyocalicin based ELISA and the VWF:Ag allows the identification of type 1 and type 2 VWD patients (Table 2). The glyocalicin-based VWF:RCo ELISA performs better than the agglutination test in identifying type 2 patients. The latter is probably due to the low sensitivity of the agglutination test.

Validation of the plasma glyocalicin-based test revealed that this ELISA has the same advantages over the currently used agglutination test as has the rFGPIb α -based ELISA. The test has a low inter-assay and intra-assay variability ($CV < 11\%$) and can be readily automated. Although theoretically rFGPIb α is a more reproducible and constant source of GPIb than plasma glyocalicin, pooled human plasma nevertheless remains a better and more reproducible source of GPIb than human platelets and clearly more readily available than rFGPIb α . We demonstrated that almost any normal plasma can be used to capture glyocalicin with no major differences in the determination of VWF:RCo in test samples. The end point of the test is colorimetric and is more easily to evaluate than the aggregation curves in the agglutination test, the ELISA is sensitive with a QL of 0.0005 U/ml and minimal amounts of patient plasma are required (8 μ l) making the test ideal for use in pediatrics.

In conclusion, we have demonstrated that in the VWF:RCO ELISA, instead of rfGPIIb/IIIa, plasma glycofibrinogen can be captured directly from plasma using the appropriate anti-GPIIb MAb. Our MAb 24B3 is freely available for use in other research laboratories to allow a multicenter evaluation in the determination of the VWF:RCO.

Acknowledgements

The authors are very grateful to Dr. K. Peerlinck from the Center for Molecular and Vascular Biology, KU Leuven, Belgium for providing the VWD plasmas and wish to thank Wim Noppe for the purification of platelet glycofibrinogen.

References

- Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost* 1994; 71: 520-25.
- Ewenstein BM. Von Willebrand's disease. *Annu Rev Med* 1997; 48: 525-42.
- Castaman G, Federici AB, Rodeghiero F, et al. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. *Haematologica* 2003; 88: 94-108.
- Hoylaerts MF, Nuyts K, Peerlinck K, et al. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. *Biochem J* 1995; 306 (Pt 2): 453-463.
- Howard MA, Firkin BG. Ristocetin—a new tool in the investigation of platelet aggregation. *Thromb Diath Haemorrh* 1971; 26: 362-9.
- Federici AB, Bader R, Pagani S, et al. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. *Br J Haematol* 1989; 73: 93-9.
- Macfarlane DE, Stibbe J, Kirby EP, et al. Letter: A method for assaying von Willebrand factor (ristocetin cofactor). *Thromb Diath Haemorrh* 1975; 34: 306-8.
- Brinkhous KM, Graham JE, Cooper HA, et al. Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test. *Thromb Res* 1975; 6: 267-72.
- Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. *Pathology* 1997; 29: 385-91.
- Vanhoorelbeke K, Cauwenberghs N, Vauterin S, et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. *Thromb Haemost* 2000; 83: 107-13.
- Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, et al. Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. *Semin Thromb Hemost* 2002; 28: 161-6.
- Okumura T, Jamieson GA. Platelet glycofibrinogen: a single receptor for platelet aggregation induced by thrombin or ristocetin. *Thromb Res* 1976; 8: 701-6.
- Yamamoto K, Kosaki G, Suzuki K, et al. Cleavage site of calcium-dependent protease in human platelet membrane glycoprotein Ib. *Thromb Res* 1986; 43: 41-55.
- McGowan EB, Yeo KT, Detwiler TC. The action of calcium-dependent protease on platelet surface glycoproteins. *Arch Biochem Biophys* 1983; 227: 287-301.
- Wicki AN, Clemetson KJ. Structure and function of platelet membrane Glycoprotein-Ib and Glycoprotein-V – effects of leukocyte elastase and other proteases on platelets response to Von Willebrand-Factor and Thrombin. *Eur J Biochem* 1985; 153: 1-11.
- Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. *Blood* 2003; 102: 4229-35.
- Coller BS, Kalomiris E, Steinberg M, et al. Evidence that glycofibrinogen circulates in normal plasma. *J Clin Invest* 1984; 73: 794-9.
- Beer JH, Buchi L, Steiner B. Glycofibrinogen: a new assay—the normal plasma levels and its potential usefulness in selected diseases. *Blood* 1994; 83: 691-702.
- Steinberg MH, Kelton JG, Coller BS. Plasma glycofibrinogen. An aid in the classification of thrombocytopenic disorders. *N Engl J Med* 1987; 317: 1037-42.
- van den Oudenrijn S, Bruin M, Folman CC, et al. Three parameters, plasma thrombopoietin levels, plasma glycofibrinogen levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. *Br J Haematol* 2002; 117: 390-8.
- Cauwenberghs N, Ajzenberg N, Vauterin S, et al. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction. *Haemostasis* 2000; 30: 139-48.
- Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Iba reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Iba. *Blood* 2001; 98: 652-60.
- Loscalzo J, Handin RI. Platelet glycofibrinogen. *Methods Enzymol* 1992; 215: 289-94.
- Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. *Haemophilia* 2002; 8: 607-21.
- Federici AB, Canciani MT, Forza I, et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ib alpha for the diagnosis of patients with low von Willebrand factor levels. *Haematologica* 2004; 89: 77-85.